Health Care • Biotechnology: Pharmaceutical Preparations
$0.84 ▼ -0.01
(-1.17%)
MKT CAP: $52.6M • VOL: 248.6K
52W L $1 52W H $4
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
CNTB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $64.0K | $26.0M | $0 |
| YoY Revenue Growth % | -99.8% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$58.1M | -$22.5M | -$69.1M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$55.5M | -$15.6M | -$62.1M |
| EBITDA (Normalized) | -$57.7M | -$21.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$51.2M | -$23.6M | -$47.7M |
| Capital Expenditures (CapEx) | $434.0K | $750.0K | — |
| Free Cash Flow (FCF) | -$51.6M | -$24.4M | -$47.7M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $38.3M | $78.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $42.0M | $92.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNTB.